Comparison
GHRP-2 vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
158861-67-7
2179963-22-7
Molecular weight
817.93 g/mol
4727 g/mol
Half-life
0.5 h
168 h
Sequence
D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
4
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2